Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/521—Chemokines
  • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/475—Growth factors; Growth regulators
  • C07K14/49—Platelet-derived growth factor [PDGF]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/475—Growth factors; Growth regulators
  • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the invention relates to the field of synthetic peptides and analogs of heparin-binding growth factors, including homodimeric synthetic heparin-binding growth factor analogs wherein two sequences are branched from a single branch point, the single branch point including at least one trifunctional amino acid residues, which branch point is further covalently bonded to a heparin-binding sequence.
• the invention further relates to the clinical uses of such analogs as soluble drugs and as coatings for medical devices.
• heparin-binding growth factors constitute a large class of growth factors that includes the 23 fibroblast growth factors identified to date (FGFs 1- 23), HBBM (heparin-binding brain mitogen), HB-GAF (heparin-binding growth associated factor), HB-EGF (heparin-binding EGF-like factor) HB-GAM (heparin-binding growth associated molecule), TGF- ⁇ (transforming growth factor- ⁇ ), TGF- ⁇ s (transforming growth factor- ⁇ s), PDGF (platelet-derived growth factor), EGF (epidermal growth factor), VEGF (vascular endothelial growth factor), IGF-I (insulin-like growth factor-1), IGF-2 (insulin-like growth factor-2), HGF (hepatocyte growth factor), IL-I (interleukin-1), IL-2 (interleukin-2), IFN- ⁇ (interferon- ⁇ ), IFN- ⁇ (interferon- ⁇ ), TNF- ⁇ (tumor necrosis, HBGF-binding
• HBGFR heparin-binding growth factor receptor
• U.S. patent 6,235,716 to Ben-Sasson discloses analogs of angiogenic factors.
• the analogs are branched multivalent ligands that include two or more angiogenic homology regions connected by a multilinker backbone.
• U.S. patent 5,770,704 discloses conjugates for activating receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily.
• the conjugates include at least two ligands capable of binding to the cognate receptor, so that the binding of the respective ligands induces oligomerization of these receptors.
• the ligands disclosed in the '704 patent are linked by covalent attachment to various nonproteinaceous polymers, particularly hydrophilic polymers, such as polyvinylalcohol and polyvinylpyrrolidone, and the polyvinylalkene ethers, including polyethylene glycol and polypropylene glycol.
• the ligands include hepatocyte growth factor (HGF) peptide variants that each bind HGF receptor, thereby causing receptor dimerization and activation of the biological activity of the HGF receptor dimer.
• HGF hepatocyte growth factor
• U.S. patent 6,284,503 discloses a composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces and hydrophobic coated surfaces for cell adhesion, cell growth, cell sorting and biological assays.
• the composition is a biomolecule conjugated to a reactive end group activated polymer.
• the end group activated polymer includes a block copolymer surfactant backbone and an activation or reactive group.
• the block copolymer may be any surfactant having a hydrophobic region capable of adsorbing onto a hydrophobic surface, and a hydrophilic region which extends away from the surface when the hydrophobic region is adsorbed onto the hydrophobic surface.
• the biomolecules that may be conjugated to the end group activated polymer include natural or recombinant growth factors, such as PDGF, EGF, TGF ⁇ , TGF ⁇ , NGF, IGF-I, IGF-H, GH and GHRF, as well as multi-CSF(II-3), GM-CSF, G-CSF, and M-CSF.
• natural or recombinant growth factors such as PDGF, EGF, TGF ⁇ , TGF ⁇ , NGF, IGF-I, IGF-H, GH and GHRF, as well as multi-CSF(II-3), GM-CSF, G-CSF, and M-CSF.
• FGFs fibroblast growth factors
• patent 6,294,359 to Fiddes et al. These disclosures relate to FGF homologs or analogs that are either conjugated to a toxic moiety and are targeted to the FGF receptor-bearing cells; or are homologs or analogs that modulate the biological pathways through the signal transduced by the FGF receptor upon binding by the FGF homolog or analog.
• a series of patent applications to Kochendoerfer et al. disclose polymer- modified proteins, including synthetic chemokines and erythropoiesis stimulating proteins. See, for example, International Publications WO 02/04105, WO 02/19963 and WO 02/20033.
• the oligomerization domains disclosed are homodimeric domains, wherein a single FGF receptor affinity fusion protein is linked to a single domain, such as a leucine zipper, which in turn is linked to a similar molecule by means of cysteine residues at both the amino and carboxy termini of the leucine zippers, such that two parallel leucine zippers, each with a single FGF receptor affinity fusion protein, are cross-linked by means of disulfide bonds.
• fusion proteins may include a heparin binding domain, such as the use of jun as a multimerization domain, which is asserted to be a heparin binding domain.
• compositions disclosed by Ballinger and Kavanaugh are all composed of a single receptor-binding sequence covalently attached to an oligomerization domain, whereby two or more similar oligomerization domains, each with a single receptor-binding sequence, are conjoined by means of either an association provided by the oligomerization domain, or alternatively, are chemically cross-linked to provide for the covalent bonding of the individual components.
• a series of applications with some inventors in common including U.S. Patent Application No. 10/644,703, entitled Synthetic Heparin-Binding Growth Factor Analogs, filed on August 19, 2003, and U.S. Patent Application Serial No.
• compositions each include a receptor-binding domain.
• none of the disclosed compositions further include two receptor-binding domains linked to a single residue through a terminal group and a side chain group of the single residue.
• new peptide analogs of HBGFs particularly for those that function as agonists, and preferably those that contain two receptor-binding domains specific for a HBGFR.
• One aspect of the present invention is a heparin-binding growth factor analog of formula I:
• each X is a peptide chain that (i) has a minimum of three amino acid residues, (ii) has a maximum of about fifty amino acid residues, and (iii) binds a heparin- binding growth factor receptor (HBGFR);
• R 1 is a single trifunctional amino acid residue covalently bonded to each X;
• Each R 2 is independently a linker comprising a chain from 0 to about 20 backbone atoms including carbon, oxygen, sulfur, nitrogen and mixtures thereof covalently bonded to R 1 and X;
• Each R 3 is hydrogen (H) such that the terminal group is NH 2 , or is an acyl group with a linear or branched C 1 to Ci 7 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH 2 , NH 3 + , or NH group or a corresponding acylated derivative;
• R 4 is OH such that the terminal group is a carboxyl, NH 2 , an acyl group with a linear or branched Ci to Ci 7 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH 2 , NH 3 + , or NH group or a corresponding acylated derivative, Or NH-R 3 ;
• Y is a linker comprising a chain from 0 to about 50 backbone atoms covalently bonded to Ri and Z;
• Z is a non-signaling peptide chain that includes a heparin binding domain, comprising an amino acid sequence that comprises (i) a minimum of one heparin binding motif, (ii) a maximum of about ten heparin binding motifs, and (iii) a maximum of about thirty amino acids.
• Y further comprises a linker that (i) is hydrophobic, (ii) comprises a chain of a minimum of about 9 and a maximum of about 50 atoms, and (iii) is not found in the natural ligand of the heparin- binding growth factor receptor (HBGFR) which X binds.
• HBGFR heparin- binding growth factor receptor
• heparin-binding growth factor analog of formula I-IV has an avidity for heparin such that the synthetic heparin-binding growth factor analog binds heparin in 0.15 M NaCl, but is eluted by 1 M
• Another aspect of the present invention provides a heparin-binding growth factor analog of formula II:
• Ri of the heparin- binding growth factor analog of formula II is an L- or D-diamine amino acid residue selected from the group consisting of 2,3 diamino propionyl amino acid, 2,4 diamino butylic amino acid, lysine and ornithine.
• Another aspect of the present invention provides a heparin-binding growth factor analog of formula EI:
• Yet another aspect of the present invention provides a heparin-binding growth factor analog of of formula IV:
• Ri is a trifunctional amino acid wherein the side chain of R 1 comprises a reactive sulfhydryl
• R2 comprises a trifunctional amino acid wherein the side chain comprises a reactive sulfhydryl, wherein R 2 is covalently bonded to R 1 by a disulfide bond.
• R 1 and R 2 are each independently an L- or D- 3-mercapto amino acid selected from the group consisting of L- or D-cysteine, L- or D- penicillamine, 3-mercapto phenylalanine, and a derivative of any of the foregoing.
• Another aspect of the present invention provides for a heparin-binding growth factor analog of formula V:
• Prg Grp is OH or a carboxy terminus protecting group
• C is carbon, H is hydrogen, N is nitrogen, O is oxygen and S is sulfur. All other features are as represented for formula I.
• Still another aspect of the present invention provides a heparin-binding growth factor analog of formula VI:
• R 1 is a trifunctional amino acid wherein the side chain comprises a first reactive group
• R 2 comprises a trifunctional amino acid wherein the side chain comprises a second reactive group, wherein R 2 is covalently bonded to Ri by a covalent bond between the first reactive group and the second reactive group.
• AU other features are as represented for formula I.
• Still another aspect of the present invention provides a heparin-binding growth factor analog comprising a synthetic peptide having two sequences branched from a single residue, the two sequences being the same and binding specifically to a heparin- binding growth factor receptor, and a sequence comprising a non-growth factor heparin- binding sequence covalently bonded to the single residue.
• the single residue comprises a trifunctional amino acid residue.
• non-growth factor heparin-binding sequence is covalently bonded to the single residue by means of a linker.
• N still another aspect provides a heparin-binding growth factor analog having a backbone chain from 2 to about 50 atoms.
• Y of any of formulas I- VI comprises between one and about thirty- three ethylene glycol units. [0032] According to another aspect of the present invention, Y of any of formulas
• I- VI comprises a branched or unbranched, saturated or unsaturated alkyl chain of between one and about twenty carbon atoms.
• Y of any of formulas I- VI comprises [NH 2 -(CH 2 ) p CO] q wherein p is from 1 to about 10 and q is from 1 to about 20.
• Y of any of formulas I- VI comprises a peptide sequence comprising from one to about 16 GIy residues.
• Z of any of formulas I- VI is BxBB or BBBxxB, wherein each B is independently lysine, arginine, ornithine, or histidine, and each x is a independently a naturally occurring amino acid.
• Z of any of formulas I- VI comprises at least two heparin-binding motifs.
• R 1 and Y of any of formulas I- VI comprise an amide, disulfide, thioether, Schiff base, reduced Schiff base, imide, secondary amine, carbonyl, urea, hydrazone or oxime bond.
• covalent bonds between Ri and each X of any of formulas I- VI comprise an amide, disulfide, thioether, Schiff base, reduced Schiff base, imide, secondary amine, carbonyl, urea, hydrazone or oxime bond.
• the covalent bonds between Y and Z of any of formulas I- VI comprise an amide, disulfide, thioether, Schiff base, reduced Schiff base, imide, secondary amine, carbonyl, urea, hydrazone or oxime bond.
• X in any of formulas I-VI is any of SEQ ID NO:7 to SEQ ID NO: 107, a portion thereof, a homolog thereof, or a homolog of a portion thereof, and Z comprises any of SEQ ID NO:1 to SEQ ID NO:6.
• VI comprises between one and about three amino acid residues selected from the group consisting of glycine, a straight chain amino carboxylic acid, a bifunctional amino-PEG- acid spacer and combinations thereof.
• Y of any of formulas I-VI comprises between one and about ten amino acid residues selected from the group consisting of glycine, a linear chain amino carboxylic acid, a bifunctional amino-PEG-acid spacer and combinations thereof.
• X of any of formulas I-VI comprises an amino acid sequence found in any of FGF-I, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-Il, FGF-12, FGF- 13, FGF- 14, FGF-15, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, FGF-23, HBBM (heparin- binding brain mitogen), HB-GAF (heparin-binding growth associated factor), HB-EGF (heparin-binding EGF-like factor) HB-GAM (heparin-binding growth associated molecule, also known as pleiotrophin, PTN, HARP), TGF- ⁇ (transforming growth f actor- ex), TGF- ⁇ s (transforming growth factor- ⁇ s), VEGF (vascular endothelial growth factor), EGF (epidermal growth
• a pharmaceutical composition comprises the heparin-binding growth factor analog of any of formulas I- VI or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.
• Fig. 1 illustrates an RP-HPLC profile for the SDl-I analog according to one embodiment of the present invention.
• Fig. 2 illustrates a graph of SDF-I and SDl-I analog concentration dependent induction of cell proliferation according to one embodiment of the present invention.
• Fig. 3 illustrates a bar graph of SDF-I and SDl-I analog induced cell migration according to one embodiment of the present invention.
• Fig. 4 illustrates a RP-HPLC profile for a PDGF analog according to one embodiment of the present invention according to one embodiment of the present invention.
• Fig. 5 illustrates results from a cell proliferation assay with PDGF analog
• FIG. 6 illustrates analysis by RP-HPLC of PBA2-1C analog according to one embodiment of the present invention according to one embodiment of the present invention.
• Fig. 7 illustrates the effect of analog PBA2-1 on cell proliferation according to one embodiment of the present invention according to one embodiment of the present invention.
• Fig. 8 illustrates a dose-dependant suppression of the activity of BMP-7 by
• FIG. 9 illustrates augmented cellular growth by GCSF-I analog according to one embodiment of the present invention.
• Each synthetic HBGF analog of the invention contains two substantially similar sequences (homodimeric sequences) that are analogs of a particular HBGF that binds to a HBGFR, or alternatively that bind to a HBGFR without being an analog of any particular HBGF.
• the homodimeric sequences may be derived from any portion of a HBGF.
• the synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR for any of the foregoing.
• HBGFs include any growth factor that binds selectively to heparin.
• the HBGF can be any of the known FGFs (FGF-I to FGF-23), Activin-A, HBBM (heparin-binding brain mitogen), HB-GAF (heparin-binding growth associated factor), HB-EGF (heparin-binding EGF-like factor) HB-GAM (heparin-binding growth associated molecule, also known as pleiotrophin, PTN, HARP), TGF- ⁇ (transforming growth factor- ⁇ ), TGF- ⁇ s (transforming growth factor- ⁇ s), VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), IGF-I (insulin-like growth factor-1), IGF-2 (insulin-like growth factor-2), PDGF (platelet derived growth factor),
• agents of the invention can be modified through the introduction of appropriate binding sequences to direct analogs of growth factors, cytokines, interleukins, and chemokines, which do not normally bind to heparin, to have heparin-binding affinity.
• the synthetic HBGF analog of the present invention consists essentially of the molecule of any one of formulas I to VI, i.e. the molecule of any one of formula I to VI is the major active component in the synthetic HBGF analog composition.
• Z of the synthetic HBGF analogs of formulas I to VI include amino acid residues, and optionally the region Y includes amino acid residues.
• An amino acid residue is defined as -NHRCO-, where R can be hydrogen or any organic group.
• the amino acids can be D- amino acids or L-amino acids. Additionally, the amino acids can be ⁇ -amino acids, ⁇ - amino acids, ⁇ -amino acids, or ⁇ -amino acids and so on, depending on the length of the carbon chain of the amino acid.
• HBGF analogs of the invention can include any of the twenty amino acids found naturally in proteins, i.e. alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamic acid (GIu, E), glutamine (GIn, Q), glycine (GIy, G), histidine (His, H), isoleucine, (lie, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (VaI, V).
• alanine Al, A
• arginine Arg, R
• asparagine Asn, N
• amino acids of the X, Y and Z component regions of the synthetic HBGF analogs of the invention can include any of the naturally occurring amino acids not found naturally in proteins, e.g. ⁇ -alanine, betaine (N,N,N-trimethylglycine), homoserine, homocysteine, ⁇ -amino butyric acid, ornithine, and citrulline.
• amino acids of the X, Y and Z component regions of the synthetic HBGF analogs of the invention can include any of the non-biological amino acids, i.e. those not normally found in living systems, such as for instance, a straight chain amino carboxylic acid not found in nature. Examples of straight chain amino carboxylic acids include 6-aminohexanoic acid, 7-aminoheptanoic acid, 9-aminononanoic acid and the like.
• two X regions are covalently linked to R 1 , either directly or through an R 2 group, where R 1 is a trifunctional amino acid residue, preferably a trifunctional alpha amino acid residue. It is to be appreciated that such covalent bonds may be to any chemically permitted functional group.
• the trifunctional amino acid residue is an amino acid with a reactive sulfhydryl side chain, such as cysteine
• a reactive sulfhydryl side chain such as cysteine
• one X is covalently bonded through the N-terminus amine group
• the second X is covalently bonded through the reactive sulfhydryl side chain, such as where R 2 includes a second cysteine residue covalently liked through a disulfide bond
• Y is covalently bonded to the second cysteine through the C-terminus carboxyl group thereof.
• R 1 is a diamine trifunctional amino acid residue, wherein R 1 is covalently bonded to Y through the carboxyl group of Ri, and the two X groups are covalently bonded to R 1 through the alpha amine and the epsilon amine of the side chain.
• Preferred groups for Rj thus include 2,3 diamino propionyl amino acid, 2,4 diamino butylic amino acid, lysine or ornithine.
• Particularly useful amino acid sequences as X regions of formulas I to VI include homologs of fragments of naturally occurring HBGFs that differ from the amino acid sequences of natural growth factor in only one or two or a very few positions.
• Such sequences preferably include conservative changes, where the original amino acid is replaced with an amino acid of a similar character according to well known principles; for example, the replacement of a non-polar amino acid such as alanine with valine, leucine, isoleucine or proline; or the substitution of one acidic or basic amino acid with another amino acid of the same acidic or basic character.
• the X regions of the synthetic HBGF analog can include an amino acid sequence that shows no detectable homology to the amino acid sequence of any HBGF.
• Peptides or growth factor analogs useful as components of the X region of the synthetic analogs of the present invention, that have little or no amino acid sequence homology with the cognate growth factor and yet bind HBGFRs may be obtained by any of a wide range of methods, including for instance, selection by phage display. See as an example: Sidhu et al. Phage display for selection of novel binding peptides. Methods Enzymol. 328:333-63 (2000).
• the X region of the synthetic HBGF analogs of the invention can have any length that includes an amino acid sequence that effectively binds an HBGFR.
• the X regions of the synthetic HBGF analogs have a minimum length of at least approximately three amino acid residues. More preferably, the X regions of the synthetic HBGF analogs have a minimum length of at least approximately six amino acid residues. Most preferably the X regions of the synthetic HBGF analogs have a minimum length of at least approximately ten amino acid residues.
• the X regions of the synthetic HBGF analogs of the invention preferably also have a maximum length of up to approximately fifty amino acid residues, more preferably a maximum length of up to approximately forty amino acid residues, and most preferably a maximum length of up to approximately thirty amino acid residues.
• the R 2 regions of formulas I, IV or VI can include a chain of atoms or a combination of atoms that form a chain.
• the chains are chains of carbon atoms, that may also optionally include oxygen, nitrogen or sulfur atoms, such as for example chains of atoms formed from amino acids (e.g. amino acids found in proteins, as listed above; naturally occurring amino acids not found in proteins, such as ornithine and citrulline; or non natural amino acids, such as amino hexanoic acid; or a combination of any of the foregoing amino acids).
• amino acids e.g. amino acids found in proteins, as listed above; naturally occurring amino acids not found in proteins, such as ornithine and citrulline; or non natural amino acids, such as amino hexanoic acid; or a combination of any of the foregoing amino acids.
• the chain of atoms of the R 2 region of formulas I, IV or VI is covalently attached to X and R 1 .
• the covalent bonds can be, for example, a peptide bond or other amide bond, or a thioether or ester bond. If present, the R 2 region preferably includes a chain of a minimum of about three backbone atoms.
• the R 2 region may be formed from a chain of at least one, at least two or at least three amino acids. However, where other than peptide bonds are employed, the R 2 region may further include a cross-linking moiety.
• R 1 is Cys or another trifunctional amino acid with a reactive sulfhydryl
• the R 2 region can be a linker consisting of a sulfhydryl reactive homo-bifunctional cross linker and a second Cys, or alternatively can include a hetero-bifunctional cross-linker, such as a cross-linker linking to the sulfhydryl on the R 1 side chain and carboxyl group of X.
• the Y region of any of formulas I to VI is a linker that is sufficiently hydrophobic to non-covalently bind the HBGF analog to a polystyrene or polycaprolactone surface, or the like.
• the Y region may bind to other hydrophobic surfaces, particularly the hydrophobic surfaces formed from materials used in medical devices. Such surfaces are typically hydrophobic surfaces.
• suitable surfaces include but are not limited to those formed from hydrophobic polymers such as polycarbonate, polyester, polypropylene, polyethylene, polystyrene, polytetrafluoroethylene, expanded polytetrafluoroethylene, polyvinyl chloride, polyamide, polyacrylate, polyurethane, polyvinyl alcohol, polyurethane, poly ethyl vinyl acetate, poly(butyl methacrylate), poly(ethylene-co-vinyl acetate), polycaprolactone, polylactide, polyglycolide and copolymers of any two or more of the foregoing; siloxanes such as 2,4,6,8-tetramethylcyclotetrasiloxane; natural and artificial rubbers; glass; and metals including stainless steel, titanium, platinum, and nitinol.
• hydrophobic polymers such as polycarbonate, polyester, polypropylene, polyethylene, polystyrene, polytetrafluoroethylene, expanded polytetrafluoroethylene
• the binding of the HBGF analogs to the hydrophobic surface is of sufficient quantity to be detected by an analytical method such as an enzyme-linked immunoassay or a biological assay.
• the Y region of formulas I to VI includes a chain of atoms or a combination of atoms that form a chain.
• the chains are chains of carbon atoms, that may also optionally include oxygen, nitrogen or sulfur atoms, such as for example chains of atoms formed from amino acids (e.g.
• the chain of atoms of the Y region of formula I to VI is covalently attached to R 1 and to peptide Z.
• the covalent bonds can be, for example, peptide, amide, thioether or ester bonds.
• the Y region includes a chain of a minimum of about nine backbone atoms. More preferably, the Y region includes a chain of a minimum of about twelve atoms.
• the Y region includes a chain of a minimum of about fifteen atoms.
• the Y region may be formed from a chain of at least four, at least five or at least six amino acids.
• the Y region may be formed from a chain of at least one, at least two, or at least three aminohexanoic acid residues.
• the Y region includes a chain of a maximum of about fifty atoms. More preferably, the Y region includes a chain of a maximum of about forty-five atoms. Most preferably, the Y region includes a chain of a maximum of about thirty-five atoms.
• the Y region may be formed from a chain of up to about twelve, up to about fifteen, or up to about seventeen amino acids.
• the amino acid sequence of the Y region is preferably an artificial sequence, i.e. it does not include any amino acid sequence of four or more amino acid residues found in a natural ligand of a HBGF.
• the Y region includes a hydrophobic amino acid residue, or a chain of hydrophobic amino acid residues.
• the Y region can, for example, include one or more straight chain amino carboxylic acids, such as for example aminohexanoic acid residues, such as one, two, three or more aminohexanoic acid residues.
• the Y region can include up to about twelve, up to about fifteen, or up to about seventeen ethylene glycol residues.
• the Y region can include a combination of amino acid hydrophobic residues.
• the Y region of the molecule can include a branched or unbranched, saturated or unsaturated alkyl chain of between one and about twenty carbon atoms.
• the Y region can include a chain of hydrophilic residues, such as for instance, ethylene glycol residues.
• the Y region can include at least about three, or at least about four, or at least about five ethylene glycol residues.
• the Z region of the molecule of formula I is a heparin-binding region and can include one or more heparin-binding motifs, BBxB or BBBxxB as described by Verrecchio et al. J.Biol.Chem. 275:7701 (2000).
• the Z region can include both BBxB and BBBxxB motifs (where B represents lysine, arginine, or histidine, and x represents a naturally occurring, or a non-naturally occurring amino acid).
• the heparin-binding motifs may be represented by the sequence [KR] [KR] [KR]X(2) [KR] (SEQ ID NO:1), designating the first three amino acids as each independently selected from lysine or arginine, followed by any two amino acids and a sixth amino acid which is lysine or arginine.
• the Z region may include at least one, at least two, at least three or at least five heparin-binding motifs. Where there are more than one heparin-binding motifs, the motifs may be the same or different.
• the Z region includes up to a maximum of about ten heparin-binding motifs.
• the Z region includes at least four, at least six or at least eight amino acid residues. Further, in certain embodiments the Z region includes up to about twenty, up to about, twenty-five, or up to about thirty amino acid residues.
• the avidity of the Z region for heparin is determined by the particular heparin-binding motifs selected and the number of such motifs in Z. Thus for particular applications both the selection and number of such motifs may be varied to provide optimal heparin binding of the Z region.
• the amino acid sequence of the Z region is
• RKRKLERIAR (SEQ ID NO:2).
• the amino acid sequence of the Z region is RKRKLGRIAR (SEQ ID NO:3).
• the amino acid sequence of the Z region is RKRKLWRARA (SEQ ID NO:4).
• the amino acid sequence of the Z region is RKRLDRIAR (SEQ ID NO:5), providing a heparin-binding motif derived from a modification of the sequence at residues 270-279 of the Jun/AP-1 DNA binding domain (Busch et al. Trans-Repressor Activity of Nuclear Glycosaminoglycans on Fos and Jun/AP-1 Oncoprotein-mediated Transcription. J. Cell Biol.
• the amino acid sequence of the Z region is RKRKLERIARC (SEQ ID NO:6).
• detection reagents such as fluorochromes, radioisotopes and other detectable markers, to the Z region, as well as the opportunity to link toxins, immunogens and the like.
• Heparin-binding domains that bear little or no sequence homology to known heparin-binding domains are also contemplated in the present invention.
• heparin-binding means binding to the -NHSO 3 " and sulfate modified polysaccharide, heparin, and also binding to the related modified polysaccharide, heparan.
• Such domains are contemplated to exhibit binding in physiological solutions including
• the Z region of the synthetic HBGF analogs of the present invention confers the property of binding to heparin in low salt concentrations, up to about 0.15 M
• NaCl optionally up to about 0.48 M NaCl, forming a complex between heparin and the Z region of the factor analog.
• the complex can be dissociated in 1 M NaCl to release the synthetic HBGF analog from the heparin complex.
• the Z region is a non-signaling peptide. Accordingly, when used alone the
• Z region binds to heparin which can be bound to a receptor of a HBGF, but the binding of the Z region peptide alone does not initiate or block signaling by the receptor.
• the C-terminus of the Z region may be blocked or free.
• the C terminus of the Z region may be the free carboxyl group of the terminal amino acid, or alternatively, the C terminus of the Z region may be a blocked carboxyl group, such as for instance, an amide group.
• alkene includes unsaturated hydrocarbons that contain one or more double carbon-carbon bonds. Examples of such alkene groups include ethylene, propene, and the like.
• alkenyl includes a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing at least one double bond; examples thereof include ethenyl, 2- propenyl, and the like.
• alkyl groups specified herein include those alkyl radicals of the designated length in either a straight or branched configuration.
• alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
• aryl includes a monovalent or bicyclic aromatic hydrocarbon radical of 6 to 12 ring atoms, and optionally substituted independently with one or more substituents selected from alkyl, haloalkyl, cycloalkyl, alkoxy, alkythio, halo, nitro, acyl, cyano, amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, or alkoxy- carbonyl.
• substituents selected from alkyl, haloalkyl, cycloalkyl, alkoxy, alkythio, halo, nitro, acyl, cyano, amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, or alkoxy- carbonyl.
• Examples of an aryl group include phenyl, biphenyl, naphthyl, 1-naphthyl, and
• aralkyl includes a radical - R a R b where R a is an alkylene (a bivalent alkyl) group and R b is an aryl group as defined above.
• R a is an alkylene (a bivalent alkyl) group and R b is an aryl group as defined above.
• aralkyl groups include benzyl, phenylethyl, 3-(3-chloro ⁇ henyl)-2-methylpentyl, and the like.
• aliphatic includes compounds with hydrocarbon chains, such as for example alkanes, alkenes, alkynes, and derivatives thereof.
• acyl includes a group RCO-, where R is an organic group.
• R is an organic group.
• An example is the acetyl group CH 3 CO-.
• a peptide is most usually acylated at the N-terminus.
• An "amide” includes compounds that have a trivalent nitrogen attached to a carbonyl group (-CO-NH 2 ).
• An "amine” includes compounds that contain an amino group (-NH 2 ).
• a "diamine amino acid” is an amino acid or residue containing two reactive amine groups and a reactive carboxyl group. Representative examples include 2,3 diamino propionyl amino acid, 2,4 diamino butylic amino acid, lysine or ornithine.
• homologous refers to peptides that differ in amino acid sequence at one or more amino acid positions when the sequences are aligned.
• amino acid sequences of two homologous peptides can differ only by one amino acid residue within the aligned amino acid sequences of five to ten amino acids.
• two homologous peptides of ten to fifteen amino acids can differ by no more than two amino acid residues when aligned.
• two homologous peptides of fifteen to twenty or more amino acids can differ by up to three amino acid residues when aligned.
• homologous peptides can differ by up to approximately 5%, 10%, 20% or 25% of the amino acid residues when the amino acid sequences of the two peptide homologs are aligned.
• a "trifunctional amino acid” is an amino acid or residue with three reactive groups, one the N-terminus amine, a second the C-terminus carboxyl, and the third comprising all or a part of the side chain.
• Trifunctional amino acids thus include, by way of example only, diamine amino acids; amino acids with a reactive sulfhydryl group in the side chain, such as mercapto amino acids including cysteine, penicillamine, or 3-mercapto phenylalanine; amino acids with a reactive carboxyl group in the side chain, such as aspartic acid and glutamic acid; and amino acids with a reactive guanadium group in the side chain, such as arginine.
• FGF Synthetic Analogs In another particular aspect, the invention provides a synthetic FGF peptide analog.
• the X region of the molecule of formulas I to VI can include an amino acid sequences found in an FGF, such as for instance FGF-2 or FGF-7.
• the X regions can include sequences not found in the natural ligand of the FGFR bound by the molecule.
• VI are not necessarily hydrophobic, and thus, if present, can be polar, basic, acidic, hydrophilic or hydrophobic.
• FGF peptide analogs can include any amino acid, or polar, ionic, hydrophobic or hydrophilic group.
• the X region of synthetic FGF peptide analogs can include an amino acid sequence that is 100% identical to an amino acid sequence found in a fibroblast growth factor or an amino acid sequence homologous to the amino acid sequence of a fibroblast growth factor.
• the X region can include an amino acid sequence that is at least about 50%, at least about 75%, or at least about 90% homologous to an amino acid sequence from a fibroblast growth factor.
• the fibroblast growth factor can be any fibroblast growth factor, including any of the known or yet to be identified fibroblast growth factors.
• the synthetic FGF analog of the invention is an agonist of the HBGFR.
• the synthetic HBGF analog initiates a signal by the HBGFR.
• the synthetic FGF analog of the invention is an antagonist of the HBGFR.
• the synthetic HBGF analog blocks signaling by the HBGFR.
• FGF analog is an analog of FGF-2 (also known as basic FGF, or bFGF).
• FGF-2 also known as basic FGF, or bFGF.
• the binding of the synthetic FGF analog to an FGF receptor initiates a signal by the FGF receptor.
• the binding of the synthetic FGF analog to the FGF receptor blocks signaling by the FGF receptor.
• the present invention provides a synthetic FGF analog of FGF-2.
• the present invention provides a synthetic FGF analog of FGF-2, wherein the amino acid sequence of the X region is YRSRKYTSWYVALKR (SEQ ID NO:7) from FGF-2.
• the present invention provides a synthetic FGF analog wherein the amino acid sequence of the X region is NRFHSWDCIKTWASDTFVLVCYDDGSEA (SEQ ID NO:8).
• the present invention provides a synthetic FGF-2 analog wherein the amino acid sequence of the X region is HIKLQLQ AEERGVVS (SEQ ID NO:9).
• the invention provides a synthetic compound
• FGF analog of FGF-I wherein the X region is YISKKHAEKNWFVGLKK (SEQ ID NO: 10). This sequence is derived from amino acids bridging the beta 9 and beta 10 loop of FGF-I.
• an FGF-I analog is provided wherein the X region is HIQLQLSAESVGEVY (SEQ ID NO: 11), corresponding to amino acids derived from the ⁇ -4 and ⁇ -5 region of FGF-I.
• the invention provides a synthetic compound
• FGF analog of FGF-7 wherein the X region is YASAKWTHNGGEMFVALNQK (SEQ ID NO: 1).
• the X region is the amino acid sequence YNIMEIRTVA VGIVA (SEQ ID NO: 13).
• FGF receptor binding domains derived largely from targeting sequences in the C-terminus of human FGF, include the following sequences shown in
• VEGF Synthetic Analogs In another particular aspect, the invention provides a synthetic VEGF peptide analog.
• the synthetic VEGF analogs represented include, in one embodiment, a VEGF analog wherein the amino acid sequence of the X region is APMAEGGGQNHHEWKFMDV (SEQ ID NO:25).
• a synthetic VEGF peptide analog wherein the amino acid sequence of the X region is GATWLPPNPTK (SEQ ID NO:26).
• a synthetic VEGF peptide analog wherein the amino acid sequence of the X region is NFLLSWVHWSLALLLYLHHA (SEQ ID NO:27).
• BMP Synthetic Analogs In another particular aspect, the invention provides a synthetic BMP peptide analog.
• the synthetic bone morphogenic protein analogs include embodiments wherein the X region includes the amino acid sequence LYVDFSDVGWNDW (SEQ ID NO:28), AISMLYLDENEKVVL (SEQ ID NO:29), ISMLYLDENEKVVLKNY (SEQ ID NO-.30), EKVVLKNYQDMVVEG (SEQ ID NO:31), LVVKENEDLYLMSIAC (SEQ ID NO:32), AFYCHGECPFPLADHL (SEQ ID NO:33), PFPLADHLNSTNHAIVQTLVNSV (SEQ ID NO:34), TQLNAISVLYFDDSSNVILKKYRNMVV (SEQ ID NO-.87 ), and/or HELYVSFRDLGWQDWIIAPEGYAAY (SEQ ID NO:88).
• the synthetic Avinin A protein analogs include embodiments wherein the X region includes the amino acid sequence SMLYYDDGQNIIKK (SEQ ID NO:89), KKIINQGDDYYLMS (SEQ ID NO-.90), and/or SMLYYDDGQNIIKKDI (SEQ ID NO-.91).
• the synthetic G-CSF protein analogs include embodiments wherein the X region includes the amino acid sequence ASSLPQSFLLKCLEQVRKIQ (SEQ ID NO:92), LDVADFATTIWQQMEEL (SEQ BD NO:93), and/or YKLAHPEELVL (SEQ ID NO:94) [00113]
• the invention provides synthetic
• the synthetic GM-CSF protein analogs include embodiments wherein the X region includes the amino acid sequence WEHVNAIQEARRLLNL (SEQ DD NO:95), LQTRLELYKQGLRGSLTKLKGPLTMMASHYKQH (SEQ ID NO:96), and/or SFKENLKDFLLVI (SEQ ID NO:97)
• the synthetic IFN-beta protein analogs include embodiments wherein the X region includes the amino acid sequence SVQARWEAAFDLDLY (SEQ ID NO:98), YLDLDFAAEWRAQVS (SEQ ID NO:99), and/or SSSTGWNETIVENLI (SEQ ID NO:100)
• the synthetic PDGF protein analogs include embodiments wherein the X region includes the amino acid sequence KTRTEVFEISRRLIDRTNANFLVW (SEQ ID NO:101), and/or QVRKIEIVRKKPIFKK (SEQ ID NO:102) [00116]
• the invention provides synthetic
• the synthetic SDF-I protein analogs include embodiments wherein the X region includes the amino acid sequence, KPVSLSYRCPCRFFESHVA (SEQ ID NO: 103), and/or KWIQEYLEK (SEQ ID NO: 104)
• BMP, TGF and GDF (growth differentiation factor) peptide analogs as shown in Table 2 wherein the transforming growth factor family member peptides are particularly useful in augmenting the activity of endogenous or artificial BMP peptides or TGF peptides, wherein is shown (under the heading "preferred receptor binding domain") the sequence forming all or part of the X region of constructs of any of formulas I to VI.
• the X region may be synthesized in a reverse direction, such that considering the sequence AISMLYLDENEKVVL (SEQ ID NO:29) illustrated in the conventional N ⁇ C orientation, and using formula II, the first amino acid bound to either the R 1 side chain or N-terminus amine is the N-terminus amino acid residue (bound through its carboxyl group thereby forming a peptide bond), the second amino acid bound to the N-terminus amino acid residue is the 2 position residue, and so on, and the compounds nonetheless retain biological activity and specifically bind to a BMP receptor.
• sequence AISMLYLDENEKVVL SEQ ID NO:29
• such a construct has, based on a conventional N — > C orientation, a reverse sequence, in that it is the carboxyl group of the conventional N-terminus amino acid residue that forms a peptide bond with an amine of Ri where Ri is a diamine amino acid.
• a reverse sequence in that it is the carboxyl group of the conventional N-terminus amino acid residue that forms a peptide bond with an amine of Ri where Ri is a diamine amino acid.
• the X region is the sequence LVVKENEDLYLMSIA (SEQ ID NO:57) (again considering the sequence in the conventional N ⁇ C orientation.
• LVVKENEDLYLMSIA include but are not limited to YNKLVVKENEDLYLMSI (SEQ ID NO:58), KKLIVNSSEDFYL (SEQ ID NO:59), WDNWGVDSFDVYL (SEQ ID NO:60), GEVVMDQYNKLVVKE (SEQ ID NO:61), LHDALPFPCEGHCYFA (SEQ ID NO:62), VSNVLTQVIAHNTSNLHDALPFP (SEQ ID NO:63), and LVVKENEDLYLMSIAC (SEQ ID NO:64).
• each of the R 2 regions of formula I are different, and in formulas IV and VI only one Ri group is provided. Even in formula I it is contemplated that such regions may differ; for example, in formula I the Ri may be a diamine amino acid, such as lysine. It is possible to utilize an orthogonal protecting group during synthesis to protect either the alpha amine or epsilon amine, to thereafter add one or amino acid residues or other groups to form an R 2 group, and then to remove the orthogonal protecting group, and proceed with parallel synthesis of the X groups from the deprotected amine on Ri and the terminal amine on R 2 .
• an orthogonal protecting group during synthesis to protect either the alpha amine or epsilon amine, to thereafter add one or amino acid residues or other groups to form an R 2 group, and then to remove the orthogonal protecting group, and proceed with parallel synthesis of the X groups from the deprotected amine on Ri and the terminal amine on R 2 .
• Methods of synthesizing the heparin-binding growth factor analogs can be achieved by any of a variety of chemical methods well known in the art. Such methods include bench scale solid phase synthesis and automated peptide synthesis in any one of the many commercially available peptide synthesizers. Preferably, the synthesizer has a per cycle coupling efficiency of greater than 99 percent.
• the analogs of the present invention can be produced by stepwise synthesis or by synthesis of a series of fragments that can be coupled by similar well known techniques. See, for instance, Nyfeler, Peptide synthesis via fragment condensation. Methods MoI. Biol. 35:303-16 (1994); and Merrifield, Concept and early development of solid-phase peptide synthesis. Methods in Enzymol. 289:3-13 (1997). These methods are routinely used for the preparation of individual peptides. It is possible to assemble the analogs of the present invention in component parts, such as peptides constituting the X, Y and Z components thereof, and to thereafter couple such component parts to assemble the analog. See, for instance, Dawson and Kent, Synthesis of native proteins by chemical ligation.
• the compounds of the present invention are synthesized by solid phase synthesis, with the C-terminus residue of the Z region of formulas I to VI bound to resin, and the synthesis proceeding stepwise.
• Conventional protecting groups are employed as required, with deprotection either prior to, during or following cleavage of the peptide from the resin.
• additional lysine residues will conventionally be protected with a protecting group, and deprotected following synthesis.
• Peptide libraries that can be used to screen for a desired property, such as binding to an HBGFR can be prepared by adaptations of these methods. See for instance, Fox, Multiple peptide synthesis, MoI. Biotechnol. 3:249-58 (1995); and Wade and Tregear, Solid phase peptide synthesis: recent advances and applications. Austral. Biotechnol. 3:332-6 (1993).
• the synthetic HBGF analog of the invention is an agonist of the HBGFR. When bound to the HBGFR, the synthetic HBGF analog initiates a signal by the HBGFR.
• the synthetic HBGF analog of the invention is an antagonist of the HBGFR.
• the synthetic HBGF analog blocks signaling by the HBGFR.
• the invention provides a method for stimulating growth factor receptor signaling in a cell by contacting the cell with an effective amount of a synthetic HBGF analog according to formulas I to VI.
• the effective amount can be readily determined by one of skill in the art.
• the signaling can result in cytokine release from the cell, stimulation or inhibition of proliferation or differentiation of the cell, chemotaxis of the cell, stimulation or inhibition of the immune system of the mammal.
• the HBGF analogs of the invention provide a cost effective and potentially unlimited source of biologically active molecules that are useful in a number of ways, including as soluble prophylactic or therapeutic pharmaceutical agents, such as for instance for administration as a soluble drug for prevention or treatment of various diseases, including for example, uses in cancer therapy and radioprotection.
• the synthetic HBGF analogs of present invention are also useful as biologically active agents for coating of medical devices, such as for instance, sutures, implants and medical instruments to promote biological responses, for instance, to stimulate growth and proliferation of cells, or healing of wounds.
• the present invention provides a method and compositions for treating a mammal that has been exposed to a harmful dose of radiation.
• the method includes administering an effective dose of a synthetic HBGF analog of the invention which is an FGF analog to the mammal.
• the treatment is particularly useful in the prevention or treatment of mucositis, gastrointestinal syndrome (G.I. syndrome), or radionecrosis such as can result from exposure to radiation.
• the HBGF analog can be administered parenterally, orally, or topically.
• the HBGF analog can be delivered loco-regionally, e.g. on an analog coated medical device.
• the present invention provides a method for treating a mammal that has been administered a dose of a chemotherapeutic agent, to ameliorate the toxicity of the chemotherapeutic agent to the mammal.
• the mammal is a human.
• the HBGF analog is an FGF-2 analog or an FGF-7 analog.
• the invention provides a method and compositions for treating a mammal with bone injury, by providing a HBGF analog of the present invention having an X region reactive with a BMP HBGFR, such as an analog of BMP-2.
• a BMP HBGFR such as an analog of BMP-2.
• such HBGF analogs of the present invention may be administered as a pharmaceutical agent, or may be employed as an additive to bone matrix or bone graft materials.
• the invention provides a method and compositions for preparation of cell or organ implant sites.
• a homodimeric HBGF analog of FGF-2 of the present invention is administered by a percutaneous route to stimulate localized angiogenesis prior to implant of insulin-secreting pancreatic cells, and thereby improve the survival of the implanted cells.
• a homodimeric HBGF analog of FGF-2 of the present invention is administered into ischemic heart tissue prior to the implant of myocte stem cells.
• the invention provides a method and compositions to increase cellular attachment to and cellular retention on blood-contacting surfaces of medical devices.
• a homodimeric HBGF analog of VEGF of the present invention is applied on vascular graft materials such that the bound analog recruits and binds circulating endothelial stem cells from the blood, thereby resulting in endothelialization of the graft surface with resultant long-term thromboresistance being imparted to the graft.
• the invention provides a method and compositions to increase and provide for membrane-guided tissue growth.
• the invention provides a method and composition for treatment of difficult-to-treat dermal wounds, including ulcers.
• a homodimeric HBGF analog of TGF- ⁇ l is applied topically in a pharmaceutically acceptable cream or gel for treatment of ulcerated bed sores and similar difficult-to-treat dermal wounds.
• the invention provides a method and compositions to selectively increase cellular populations in vitro.
• a homodimeric HBGF analog of TGF- ⁇ l is formulated in a tissue culture medium to specifically stimulate the growth of chondrocytes, stem cells which give rise to chondrocytes, or pluripotent cells which give rise of chondrocytes.
• a homodimeric HBGF analog of VEGF may be employed to stimulate the growth of endothelial cells.
• the term "medical device” as used herein means a device that has one or more surfaces in contact with an organ, tissue, blood or other bodily fluid in an organism, preferably a mammal, particularly, a human.
• Medical devices include, for example, extracorporeal devices for use in surgery such as blood oxygenators, blood pumps, blood sensors, tubing used to carry blood, and the like which contact blood that is returned to the patient.
• the term can also include endoprostheses implanted in blood contact in a human or animal body, such as vascular grafts, stents, pacemaker leads, heart valves, and the like that are implanted in blood vessels or in the heart.
• the term can further include devices for temporary intravascular use such as catheters, guide wires, and the like that are placed in blood vessels or the heart for purposes of monitoring or repair.
• the term can further include nerve electrodes, muscle electrodes, implantable pulse generators, implantable drug pumps, and defibrillators.
• the term medical device can include sutures, graft materials, wound coverings, nerve guides, bone wax, aneurysm coils, embolization particles, microbeads, dental implants, bone prostheses, tissue scaffolds, artificial joints or a controlled release drug delivery devices.
• the surface of the medical device can be formed from any of the commonly used materials suitable for use in medical devices, such as for instance, stainless steel, titanium, platinum, tungsten, ceramics, polyurethane, polytetrafluoroethylene, extended polytetrafluoroethylene, polycarbonate, polyester, polypropylene, polyethylene, polystyrene, polyvinyl chloride, polyamide, polyacrylate, polyurethane, polyvinyl alcohol, polycaprolactone, polylactide, polyglycolide, polysiloxanes (such as 2,4,6,8-tetramethylcyclotetrasiloxane), natural rubbers, or artificial rubbers, or block polymers or copolymers thereof.
• the invention provides a method for delivering an active peptide to a mammal, the method includes (i) providing a medical device coated on its surface with a synthetic HBGF analog of formulas I to VI, the synthetic HBGF analog being bound to the surface of the medical device by non-covalent bonds; and (ii) placing the medical device onto a surface of, or implanting the medical device into, the mammal.
• the non-covalent bonds are associations between the heparin binding domain of the synthetic HBGF analog and a heparin-containing compound bound to the surface of the medical device.
• the heparin- containing compound bound to the surfade of the medical device can be any heparin- containing compound, such as for instance, benzyl-bis(dimethylsilylmethyl)oxy carbamoyl-heparin.
• the medical device is not pre-coated with a heparin-containing compound before being coated with the synthetic HBGF analog of formulas I to VI.
• HBGF analogs of this invention can be used for as an active ingredient in pharmaceutical compositions for both medical applications and animal husbandry or veterinary applications. Typically, the HBGF analog or pharmaceutical composition is used in humans, but may also be used in other mammals.
• patient is intended to denote a mammalian individual, and is so used throughout the specification and in the claims. The primary applications of this invention involve human patients, but this invention may be applied to laboratory, farm, zoo, wildlife, pet, sport or other animals.
• the HBGF analogs of this invention may be in the form of any pharmaceutically acceptable salt.
• pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids.
• Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, lithium, magnesium, potassium, and sodium salts.
• Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
• basic ion exchange resins such as
• acid addition salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
• acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, carboxylic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, malonic, mucic, nitric, pamoic, pantothenic, phosphoric, propionic, succinic, sulfuric, tartaric, p- toluenesulfonic acid, trifluoroacetic acid, and the like.
• Acid addition salts of the HBGF analogs of this invention are prepared in a suitable solvent for the HBGF analog and an excess of an acid, such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, citric, tartaric, maleic, succinic or methanesulfonic acid.
• an acid such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, citric, tartaric, maleic, succinic or methanesulfonic acid.
• suitable pharmaceutically acceptable salts may include alkali metal salts, such as sodium or potassium salts, or alkaline earth metal salts, such as calcium or magnesium salts.
• the invention provides a pharmaceutical composition that includes a
• HBGF analog of this invention and a pharmaceutically acceptable carrier.
• the carrier may be a liquid formulation, and in one embodiment a buffered, isotonic, aqueous solution.
• Pharmaceutically acceptable carriers also include excipients, such as diluents, carriers and the like, and additives, such as stabilizing agents, preservatives, solubilizing agents, buffers and the like, as hereafter described.
• the HBGF analog compositions of this invention may be formulated or compounded into pharmaceutical compositions that include at least one HBGF analog of this invention together with one or more pharmaceutically acceptable carriers, including excipients, such as diluents, carriers and the like, and additives, such as stabilizing agents, preservatives, solubilizing agents, buffers and the like, as may be desired.
• pharmaceutically acceptable carriers including excipients, such as diluents, carriers and the like, and additives, such as stabilizing agents, preservatives, solubilizing agents, buffers and the like, as may be desired.
• Formulation excipients may include polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, PEG, PEO, mannitol, sodium chloride or sodium citrate, as well as any number of simple sugars, including sucrose, dextrose, lactose and the like, and combinations of the foregoing.
• water containing at least one or more buffering constituents is preferred, and stabilizing agents, preservatives and solubilizing agents may also be employed.
• stabilizing agents, preservatives and solubilizing agents may also be employed.
• solid administration formulations any of a variety of thickening, filler, bulking and carrier additives may be employed, such as starches, sugars, fatty acids and the like.
• topical administration formulations any of a variety of creams, ointments, gels, lotions and the like may be employed.
• non-active ingredients will constitute the greater part, by weight or volume, of the preparation.
• any of a variety of measured-release, slow-release or time-release formulations and additives may be employed, so that the dosage may be formulated so as to effect delivery of a HBGF analog of this invention over a period of time.
• the HBGF analogs of the invention can be combined as the active ingredient in an admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
• the carrier may take a wide variety of forms depending on the form of preparation desired for administration, for example, oral, parenteral (including intravenous), urethral, vaginal, nasal, buccal, sublingual, or the like.
• any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets.
• oral liquid preparations such as, for example, suspensions, elixirs and solutions
• carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets.
• the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
• the form must be sterile and must be fluid to the extent that it may be administered by syringe.
• the form must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a polyol, for example glycerol, propylene glycol or liquid polyethylene glycol, suitable mixtures thereof, and vegetable oils.
• the injection may be intravenous, subcutaneous, intramuscular, intraperitoneal or other means known in the art.
• the HBGF analogs of this invention may alternatively be formulated by any means known in the art, including but not limited to formulation as tablets, capsules, caplets, suspensions, powders, lyophilized preparations, suppositories, ocular drops, skin patches, oral soluble formulations, sprays, aerosols and the like, and may be mixed and formulated with buffers, binders, excipients, stabilizers, anti-oxidants and other agents known in the art.
• Administration means may thus include administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration, nasal administration, urethral administration, vaginal administration, and the like.
• HBGF analog of this invention administered to a patient will vary between fairly wide ranges depending upon the mode of administration, the formulation used, and the response desired.
• the dosage for treatment is administration, by any of the foregoing means or any other means known in the art, of an amount sufficient to bring about the desired therapeutic effect.
• Heparin-binding growth factors The fibroblast growth factors, FGFs, constitute a family of related proteins controlling normal growth and differentiation of mesenchymal, epithelial, and neuroectodermal cell types. Homologs have been found in a wide variety of species. FGFs show a very high affinity to heparin and are therefore also referred to as heparin-binding growth factors (HBGFs). As used herein, the term HBGFs includes all FGFs.
• FGF basic FGF
• bFGF basic FGF
• HBGF-2 heparin-binding growth factor-2
• FGF FGF
• FGF FGF
• HBGF-I heparin-binding growth factor-1
• HBGF- ⁇ heparin-binding growth factor- ⁇
• fibroblast growth factors belonging to the same family include FGF-
• HBGF-3 heparin-binding growth factor-3, originally called int-2; see Fekete, Trends in Neurosci. 23:332 (2000)
• FGF-4 HBGF-4, heparin-binding growth factor-4, initially recognized as the product of the oncogene hst; see Sakamoto et al., Proc. Natl. Acad. Sci. USA 91:12368-72
• FGF-5 originally called HBGF-5, see Bates et al. Biosynthesis of human fibroblast growth factor 5. MoI. Cell. Biol. 11:1840-1845 (1991)); Burgess and Maciag, The heparin-binding (fibroblast) growth factor family of proteins. Ann. Rev.
• FGF-6 is also known as HBGF-6, and sometimes called hst-2 or oncogene hst-1 related growth factor, see Iida et al. Human hst-2 (FGF-6) oncogene: cDNA cloning and characterization. Oncogene 7:303-9 (1992); and Maries et al. Characterization of the HST-related FGF-6 gene, a new member of the fibroblast growth factor gene family. Oncogene 4:335-40 (1989).
• FGF-7 or K-FGF is also known as KGF or keratinocyte growth factor (See
• FGF-8 was found to be identical to androgen-induced growth factor, AIGF and has been well studied (See Blunt et al.
• FGF-9 was originally called glia activating factor, or HBGF-9. See
• FGF-10 is also called KGF-2, keratinocyte growth factor-2 (see Kok et al.
• FGF-related factors have been described as fibroblast growth factor homologous factors (FHFs) and are also referred to as FGF-Il (FHF-3), FGF-12 (FHF-I), FGF-13 (FHF-2, see Greene et al. Identification and characterization of a novel member of the fibroblast growth factor family. Eur. J. Neurosci. 10:1911-1925 (1998)), and FGF- 14 (FHF-4).
• FGF-15 is expressed in the developing nervous system and was identified as a gene regulated by transcription factor E2A-Pbxl. McWhirter et al. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbxl. Development 124:3221-3232 (1997).
• FGF-16 was isolated as a cDNA clone from rat heart by homology-based polymerase chain reaction expressing an FGF of 207 amino acids. FGF-16 is 73% identical to FGF-9. Miyake et al. Structure and expression of a novel member, FGF-16, of the fibroblast growth factor family. Biochem. Biophys. Res. Commun. 243:148-152 (1998).
• the cDNA encoding FGF-17 was isolated from rat embryos and encodes a protein of 216 amino acids. When expressed in 3T3 fibroblasts, mouse FGF-17 is transforming. During embryogenesis, FGF-17 is expressed at specific sites in forebrain, the midbrain-hindbrain junction, the developing skeleton and in developing arteries. See Hoshikawa et al. Structure and expression of a novel fibroblast growth factor, FGF-17, preferentially expressed in the embryonic brain. Biochem. Biophys. Res. Commun. 244:187-191 (1998); and Xu et al. Genomic structure, mapping, activity and expression of fibroblast growth factor 17. Mechanisms of Development 83:165-178 (1999).
• FGF- 18 The cDNA encoding FGF- 18 was isolated from rat embryos encoding a protein of 207 amino acids.
• FGF- 18 is a glycosylated protein and is most similar to FGF-8 and FGF-17.
• Injection of recombinant murine FGF-18 has been shown to induce proliferation in tissues of both epithelial and mesenchymal origin, particularly in liver and small intestine.
• Recombinant rat FGF-18 induces neurite outgrowth in PC12 cells.
• Recombinant murine FGF-18 protein stimulates proliferation in NIH 3T3 fibroblasts in vitro in a heparan sulfate-dependent manner.
• FGF- 18 a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. MoI. Cell. Biol. 18:6063-6074 (1998); and Ohbayashi et al. Structure and expression of the mRNA encoding a novel fibroblast growth factor, FGF-18. J. Biol. Chem. 273:18161-18164 (1998).
• FGF-19 is related distantly to other members of the FGF family. FGF-19 mRNA is expressed in several tissues including fetal cartilage, skin, and retina, as well as adult gall bladder. It is overexpressed in a colon adenocarcinoma cell line. FGF-19 is a high affinity, heparin-dependent ligand for the FGF-4 receptor. See Xie et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4 Cytokine 11:729-735 (1999). [00166] FGF-20 is expressed in normal brain, particularly the cerebellum, and in some cancer cell lines. FGF-20 mRNA is expressed preferentially in the substantia nigra pars compacta.
• FGF-20 protein induces DNA synthesis in a variety of cell types and is recognized by multiple FGF receptors.
• FGF-20 functions like an oncogene, causing a transformed phenotype when expressed in the 3T3 fibroblast cell line. These transformed cells are tumorigenic in nude mice. See Jeffers et al. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res. 61:3131-8 (2001); and Ohmachi et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem. Biophys. Res. Commun. 277:355-60 (2000).
• FGF-21 was isolated from mouse embryos. FGF-21mRNA is most abundant in the liver with lower levels in the thymus. FGF-21 is most similar to human FGF-19. See Nishimura et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492:203-6 (2000). [00168] The cDNA encoding FGF-22 (170 amino acids) was isolated from human placenta. FGF-22 is most similar to FGF-10 and FGF-7. Murine FGF-22 mRNA is expressed preferentially in the skin. FGF-22 mRNA in the skin is found preferentially in the inner root sheath of the hair follicle. See Nakatake et al. Identification of a novel fibroblast growth factor, FGF-22, preferentially expressed in the inner root sheath of the hair follicle. Biochim. Biophys. Acta 1517:460-3 (2001).
• FGF-23 is most similar to FGF-21 and FGF-19.
• the human FGF-23 gene maps to chromosome 12pl3 linked to human FGF-6 gene.
• FGF-23 mRNA is expressed mainly in the brain (preferentially in the ventrolateral thalamic nucleus) and thymus at low levels. Missense mutations in the FGF-23 gene have been found in patients with autosomal dominant hypophosphataemic rickets.
• Overproduction of FGF23 causes tumor- induced osteomalacia, a paraneoplastic disease characterized by hypophosphatemia caused by renal phosphate wasting. See Yamashita et al.
• HBBM Heparin-binding brain mitogen
• HB-GAF heparin-binding growth associated factor
• HBNF heparin-binding neurite-promoting factor
• HB-EGF heparin-binding EGF-like factor
• HB-EGF heparin-binding EGF-like factor
• HB-EGF is a monomeric heparin-binding O-glycosylated protein of 86 amino acids and is processed from a precursor of 208 amino acids.
• Several truncated forms of HB-EGF have been described.
• HB-EGF is a potent mitogen for NIH 3T3 cells, keratinocytes and smooth muscle cells, but not for endothelial cells.
• HB-EGF is a major growth factor component of wound fluid and may play an important role in wound healing. See Abraham et al. Heparin-binding EGF-like growth factor: characterization of rat and mouse cDNA clones, protein domain conservation across species, and transcript expression in tissues. Biochem. Biophys. Res. Commun. 190:125-133 (1993); Higashiyama et al. A heparin-binding growth factor secreted by macrophage like cells that is related to EGF. Science 251:936-9 (1991); and Marikovsky et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc. Natl. Acad. Sci. (USA) 90:3889-93.
• HB-GAM heparin-binding growth associated molecule
• HBNF heparin-binding neurite promoting factor
• TGF-beta exists in at least five isof orms, known TGF- ⁇ 1 , TGF- ⁇ 2,
• TGF- ⁇ 3, TGF- ⁇ 4 and TGF- ⁇ 5, that are not related to TGF- ⁇ are not related to TGF- ⁇ .
• Their amino acid sequences display homologies on the order of 70-80 percent.
• TGF- ⁇ 1 is the prevalent form and is found almost ubiquitously while the other isoforms are expressed in a more limited spectrum of cells and tissues.
• TGF-beta is the prototype of a family of proteins known as the TGF-beta superfamily. This family includes inhibins, Activin A, MIS (Mullerian activating substance) and BMPs (Bone morphogenic proteins). Burt, Evolutionary grouping of the transforming growth factor-beta superfamily. Biochem. Biophys. Res. Commun. 184:590- 5 (1992).
• Example 1 A compound of the present invention was synthesized by solid phase peptide chemistry with the general structure of formula I wherein X is a BMP- 2 receptor binding amino acid sequence having the sequence AISMLYLDEKVVL(SEQ ID NO: 105) wherein the sequence was grown in parallel from the Ri trifunctional amino acid of formula I when R 2 is 0 atoms and Ri is lysine.
• the resulting synthetic growth modulator analog is of the following specific structure:
• Ahx is 6-amino hexanoic acid, sometimes also called “6-Ahx” or "Hex”.
• the single letters are standard amino acid single letter abbreviations for the naturally coded amino acids.
• Example 2 A compound of the present invention was synthesized by solid phase peptide chemistry with the general structure of formula I wherein X is a BMP receptor binding amino acid sequence having the sequence LYFDESSNVILKK(SEQ ID NO: 106) which was grown in parallel from the Ri trifunctional amino acid of formula I when R 2 is 0 atoms and Ri is a lysine.
• the resulting synthetic growth modulator analog is of the following specific structure:
• Ahx is 6-amino hexanoic acid, sometimes also called “6-Ahx” or "Hex”.
• the single letters are standard amino acid single letter abbreviations for the naturally coded amino acids.
• Example 3 A compound of the present invention is synthesized by solid phase peptide chemistry with the general structure of formula I wherein X is a BMP-2 receptor binding amino acid sequence having the sequence
• Ahx is 6-amino hexanoic acid, sometimes also called “6-Ahx” or "Hex”.
• the single letters are standard amino acid single letter abbreviations for the naturally coded amino acids.
• Example 4 The synthetic FGF analog YRSRKYSSWYVALKRK(H-
• the Ri group of formula I was a single trifunctional amino acid residue, here a diamine amino acid, lysine (K).
• the peptide of Example 4 has an estimated molecular weight of 5681.
• Example 4 The peptide of Example 4 was assembled stepwise by solid-phase synthesis on a substituted resin, using Fmoc chemistry for temporary protection of amino groups in the repetitive cycles. Protecting groups were used as required. Branching of the chain was accomplished by stepwise growth of identical chains from the alpha amino group and side-chain amino group of a single lysyl residue. The completed peptide chain was cleaved from the resin as C-terminal amides by acidolysis, which also removed the acid- labile side-chain protecting groups.
• the peptide of Example 4 was purified by reverse phase HPLC using a C 18 column in a continuous gradient elution of 0-60% B over 60 minutes, run at 1 mL/min, where A was 0.1% trifluoroacetate in water and B was 0.1% trifluoroacetate in acetonitrile.
• the general structure of the compound of Example 4 is shown below:
• Example 5 Two peptides were synthesized as analogs of TGF as in
• H-YIWSLDTQYSKVLK H-YIWSLDTQYSKVL-AhX-AhX-RKRKLERIAR-NH2
• Example 6 A peptide was synthesized as a candidate agonist of PDGF-BB and designated PBA2-1C.
• the peptide was branched from a single lysine (K) at the R 1 position, where the N-terminus residue of the branched sequence CVRKIEIVRKK(SEQ ID NO: 107) was a cysteine (C) residue.
• the resulting construct was a cyclic peptide, with the two X regions joined by a disulfide bond at the N-terminus cysteine.
• the peptide was was purified by RP-HPLC on a C 18 column, using a linear gradient 0- 60% acetonitrile/water (0.1% trifluoroacetic acid) run over 60 min at 1 ml/min flow rate (detection at 214 nm).
• the purified peptide generated a single uniform peak on analysis by RP-HPLC as indicated in figure 6.
• SPR Surface Plasmon Resonance Analysis. Real-time biomolecular interactions were analyzed with a BIAcore 2000 system (Biacore Inc., Piscataway, NJ). Soluble PDGF receptor, recombinant chimera of human PDGF-R-alpha and PSGF-R-beta (R &D Systems, Minneapolis, MN ), was immobilized on research grade CM5 chips (Biacore Inc., Piscataway, NJ). Following activation with EDC/NHS, the receptors were immobilized on activated CM5 chips. To obtain kinetic data, different concentrations of analytes in HBS-EP buffer were injected over the sensor chip at a flow rate of 50 ⁇ l/min.
• Any suitable carboxy protecting group is employed, if desired, on the second cysteine employed forming a disulfide bridge with the cysteine at the R 1 position. Synthesis may proceed without a protecting group, but for most synthetic methods it is desirable to employ a protecting group. The protecting group may be removed following synthesis, or alternatively may be left in place.
• an ester is employed as a C-terminal protecting group, such as methyl, ethyl, benzyl or substituted benzyl esters. Other esters may be employed, including allyl esters or t-butyl esters.
• SDl-I A mimetic of SDF-I, the peptide designated SDl-I, was synthesized following standard Fmoc protocols using a NovaSyn TGR resin (EMD BioSciences, La Jolla, CA). Fmoc-amino acids including aminohexanoic acid (Ahx) were obtained from Peptides International, Inc. (Lexington, KY). SDl-I has the following sequence:
• KPVSLSYRAPARFFESHVAK(KPVSLSYRAPARFFESHVA)HXHXHXRKRKLERIAR- amide KPVSLSYRAPARFFESHVAK(KPVSLSYRAPARFFESHVA)HXHXHXRKRKLERIAR- amide.
• SDF-I was purified by RP-HPLC on a C18 column, using a linear gradient
• SDl-I on cell proliferation Sup-Tl cells were seeded at 100,000 cells per well of a 96- well plate and allowed to attach. The medium was changed to one containing low serum plus SDl-I and the cells incubated for 3 days after which time the relative cell number was determined using a commercially available kit Referring now to figure 2, data in the graph below is reported as the average ⁇ SD. Commercially-available recombinant human SDF-I (diamond) was used as a reference and positive control for comparison of proliferation stimulated by SDF-I (triangle).
• C2C12 cells using a commercially-avialable cell migration assay.
• C2C12 cells were seeded on a trans-well insert containing an 8 ⁇ m pore size polycarbonate membrane coated with a thin layer of polymerized collagen.
• the inserts were placed into wells with medium containing SDl-I. Cells that migrated through the membrane were found on the bottom of the insert membrane. These cells were stained, and the stain extracted and detected on a standard microplate reader (560 nm).
• a standard microplate reader 560 nm.
• Example 9 A mimetic of PDGF, the peptide designated PBA2-1 , was synthesized following standard Fmoc protocols using a NovaSyn TGR resin (EMD BioSciences, La Jolla, CA). Fmoc-amino acids including aminohexanoic acid (Ahx) were obtained from Peptides International, Inc. (Lexington, KY). PBA2-1 has the following sequence:
• PB A2-1 was purified by RP-HPLC on a Cl 8 column, using a linear gradient 0-60% acetonitrile/water (0.1% trifluoroacetic acid) run over 60 min at 1 ml/min flow rate (detection at 214 nm).
• the purified peptide generated a single uniform peak on analysis by RP-HPLC as is illustrated in figure 4.
• SPR Surface Plasmon Resonance Analysis. Real-time biomolecular interactions were analyzed with a BIAcore 2000 system (Biacore Inc., Piscataway, NJ). Soluble PDGF receptor, recombinant chimera of human PDGF-R-alpha and PSGF-R-beta (R &D Systems, Minneapolis, MN ), was immobilized on research grade CM5 chips (Biacore Inc., Piscataway, NJ). Following activation with EDC/NHS, the receptors were immobilized on activated CM5 chips. To obtain kinetic data, different concentrations of analytes in HBS-EP buffer were injected over the sensor chip at a flow rate of 50 ⁇ l/min.
• Peptide binding was measured in resonance units (RU). At the end of each sample injection (120 s) buffer was passed over the sensor surface to monitor the dissociation phase. Reference responses from blank flow cells were subtracted from receptor- containing flow cells for each analyte injection and the kinetic parameters for each interaction were determined by globally fitting the experimental data to a 1:1 interaction with BIAEVALUATION software (Biacore Inc., Piscataway, NJ). The association rate constant and the dissociation rate constant (ka and kd, respectively), and the equilibrium dissociation constant (K D ) are presented in the Table 4 for the receptors and PBA2-1.
• Example 10 A peptide was synthesized based on a sequence of BMP-7.
• the peptide was designated B7A1-6 and had the sequence:
• AISVLYFDDSSNVILKKK(AISVLYFDDSSNVILKK)HxHxHxRKRKLERIAR-amide [00198] This peptide was evaluated using C2C12 cells and in the presence of recombinant BMP-7 and using alkaline phosphatase production as an endpoint. Alkaline phosphatase assays were performed using mouse the pluripotent cell lines C2C12. Cells were plated in 96-well (lxlO4/well) plates and allowed 24 hours to attach. The medium was then replaced with a serum low medium containing BMP-7 and/or B7A1-6. After several days, cells were rinsed, lysed, and alkaline phosphatase activity measured using p- nitrophenylphosphate as substrate. B7A1-6 had a dose-dependant suppression of the activity of BMP-7 as indicated in figure 8.
• Example 11 A peptide was synthesized based on a sequence from G-CSF and designated GCSFl. GCSFl had the sequence: SFLLKALEQVRKIQYK(SFLLKALEQVRKIQY)HxHxHxRKRKLERIAR-amide This peptide was evaluated for augmentation of growth using M-NSF-60 cells in the presence of 0.01 ng rhGCSF. As shown in figure 9, the peptide augmented cellular growth as monitored using a commercially-available MTX kit. [00200] Although the invention has been described in detail with particular reference to these preferred embodiments, other embodiments can achieve the same results.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Toxicology (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Dermatology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Medicinal Preparation (AREA)
• Materials For Medical Uses (AREA)

Priority Applications (4)

Applications Claiming Priority (4)

Publications (2)

Family

ID=36928004

Family Applications (1)

Country Status (6)

Cited By (5)

Families Citing this family (10)

Family Cites Families (111)

• 2006
  • 2006-02-21 US US11/359,173 patent/US20080227696A1/en not_active Abandoned
  • 2006-02-22 WO PCT/US2006/006397 patent/WO2006091727A2/en active Application Filing
  • 2006-02-22 AU AU2006216676A patent/AU2006216676A1/en not_active Abandoned
  • 2006-02-22 EP EP06735882A patent/EP1855706A4/en not_active Withdrawn
  • 2006-02-22 CA CA002598688A patent/CA2598688A1/en not_active Abandoned
  • 2006-02-22 JP JP2007556427A patent/JP4897708B2/ja not_active Expired - Fee Related
• 2010
  • 2010-05-24 US US12/786,256 patent/US8101570B2/en not_active Expired - Fee Related

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events